RecruitingNCT06376097

Lung Cancer Screening Program Using Low-dose Tomography and Metabolomic Evaluation in a Public Service.

Implementation of a Lung Cancer Screening Program in a Public Service, Using Low-dose Tomography and Metabolomics Evaluation

Sponsor

AstraZeneca

Enrollment

1,000 participants

Start Date

Apr 19, 2023

Study Type

OBSERVATIONAL

Conditions

Lung Cancer

Summary

Observational study that aims to evaluate the implementation of a lung cancer screening program in a smoker population included in a public heath service.

Eligibility

Min Age: 45 YearsMax Age: 74 Years

Inclusion Criteria1

Age between 45 and 74 years old; Smoker with a smoking history of at least 30 pack-years or former smoker who has quit smoking for less than 15 years; Never having participated in a lung cancer screening program ; Signing of the free and informed consent form.

Exclusion Criteria1

Patients with chronic diseases (cardiovascular, pulmonary, hepatic, renal or metabolic) at an advanced stage that limit life expectancy or make it impossible to perform a curative surgical procedure; Patients being treated for tuberculosis or other granulomatous diseases; Patients diagnosed with previous neoplasm(s) that could develop lung metastases; Pregnant women; Patients who, for some reason, are unable to undergo low-dose chest computed tomography; Patients previously submitted to thoracic radiotherapy.